The journey of the medicine, Caplacizumab – from a publicly funded scientific breakthrough to a high-cost pharmaceutical product controlled by a multinational corporation – illustrates the contradictions of the existing drug development system.  It is a story of public investment, private capital, industrial consolidation, and the persistent question: Who ultimately benefits from medical innovation? At […] Continue reading ->